Lifespan Cardiovascular Institute

Secret Trial Patient

This study is for subjects who are hospitalized for worsening heart failure. The study will consist of screening and randomization within 36 hours of hospitalization; assessments at 8, 16, 24, 48 hours and daily thereafter while hospitalized up to day 7. Subjects will be randomized into two groups to receive once daily, placebo or Tolvaptan 30 mg during hospitalization (maximum of 7 days). All subjects will continue to receive conventional therapy, which are standard of care medicines. Patients with advanced heart failure suffer greatly and hospitalizations are frequent.

For more information, please contact:
Cardiovascular Research
The Miriam Hospital
Lori-Ann DeSimone